Why Mylan Is Poised to Keep Popping
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic pharmaceutical company Mylan has earned a respected four-star ranking.
With that in mind, let's take a closer look at Mylan and see what CAPS investors are saying about the stock right now.
Canonsburg, Pa. (1961)
CEO Heather Bresch
Return on Equity (average, past 3 years)
$409.5 million / $5.7 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.
Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Mylan may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Mylan Is Poised to Keep Popping originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.